Hubbry Logo
Anti-streptolysin OAnti-streptolysin OMain
Open search
Anti-streptolysin O
Community hub
Anti-streptolysin O
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Anti-streptolysin O
Anti-streptolysin O
Anti-streptolysin O
View on Wikipedia
from Wikipedia

Anti-streptolysin O (ASO or ASLO) is the antibody made against streptolysin O, an immunogenic, oxygen-labile streptococcal hemolytic exotoxin produced by most strains of group A and many strains of groups C and G Streptococcus bacteria. The "O" in the name stands for oxygen-labile; the other related toxin being oxygen-stable streptolysin-S. The main function of streptolysin O is to cause hemolysis (the breaking open of red blood cells)—in particular, beta-hemolysis.

Increased levels of ASO titre in the blood could cause damage to the heart and joints. In most cases, penicillin is used to treat patients with increased levels of ASO titre.

Clinical significance

[edit]

When the body is infected with streptococci, it produces antibodies against the various antigens that the streptococci produce. ASO is one such antibody. A raised or rising levels can indicate past or present infection. Historically it was one of the first bacterial markers used for diagnosis and follow up of rheumatic fever or scarlet fever. Its importance in this regard has not diminished.[citation needed]

Since these antibodies are produced as a delayed antibody reaction to the above-mentioned bacteria, there is no normal value. The presence of these antibodies indicates an exposure to these bacteria. However, as many people are exposed to these bacteria and remain asymptomatic, the mere presence of ASO does not indicate disease.

A titre has significance only if it is greatly elevated (> 200), but a rise in titre demonstrated in paired blood samples taken days apart is more informative for diagnosis. The antibody levels begin to rise after 1 to 3 weeks of strep infection, peaks in 3 to 5 weeks and falls back to insignificant levels in 6 months. Values need to be correlated with a clinical diagnosis.[citation needed] The aim is to convert it .

Estimation

[edit]
Further information: serology

It is done by serological methods like latex agglutination or slide agglutination. ELISA may be performed to detect the exact titre value. To detect the titre value, by a non-ELISA method, one has to perform the above agglutination using a serial dilution technique.[citation needed]

Mechanism of action

[edit]
Further information: rheumatic fever

These antibodies produced against the bacteria cross-react with human antigens (mainly collagen) and hence attack the cellular matrix of various organs, mainly the heart, joints, skin, brain, etc.[citation needed]

Antistreptolysin O titre

[edit]

Antistreptolysin O titre (AS(L)O titer or AS(L)OT) is a measure of the blood plasma levels of antistreptolysin O antibodies used in tests for the diagnosis of a streptococcal infection or indicate a past exposure to streptococci. The ASOT helps direct antimicrobial treatment and is used to assist in the diagnosis of scarlet fever, rheumatic fever, and post infectious glomerulonephritis.[citation needed]

A positive test usually is > 200 units/mL,[1] but normal ranges vary from laboratory to laboratory and by age.[2]

The false negatives rate is 20 to 30%.[1] If a false negative is suspected, then an anti-DNase B titre should be sought. False positives can result from liver disease and tuberculosis.[1]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Anti-streptolysin O

View on Grokipedia
from Grokipedia
Anti-streptolysin O (ASO), also known as antistreptolysin O , is an immunoglobulin produced by the human in response to streptolysin O, a hemolytic secreted by group A , such as . This typically becomes detectable in the approximately one week after and peaks between three and five weeks, remaining elevated for several months as evidence of a prior streptococcal exposure. The ASO response serves as a serological marker for diagnosing infections caused by these , particularly when direct detection methods like throat cultures are inconclusive or delayed. The primary clinical application of measuring ASO levels is through the antistreptolysin O titer (ASOT) , which quantifies concentrations to confirm recent or ongoing streptococcal infections and their nonsuppurative complications. This test is especially valuable for identifying post-streptococcal sequelae, including acute —characterized by symptoms such as fever, joint pain, and —and post-streptococcal , which may present with , , and . Elevated ASO titers are observed in over 80% of acute cases and in the majority (approximately 70-80%) of post-streptococcal cases following pharyngeal infections, though serial testing (e.g., two weeks apart) is often recommended to detect rising levels indicative of an acute response. Normal reference ranges vary by age, , and method; typical upper limits include ≤70 IU/mL for children under 5 years, ≤300-640 IU/mL for ages 5–17, and ≤200 IU/mL for adults 18 and older. While the ASO test is not suitable for diagnosing active —where rapid antigen tests or cultures are preferred—it plays a crucial role in , particularly in resource-limited settings or when complications arise weeks after initial infection. Limitations include potential false negatives in up to 20% of cases, reduced sensitivity following early antibiotic treatment, and the need for complementary assays like anti-DNase B for infections originating from rather than the . In regions with high streptococcal disease burden, such as parts of and , ASO testing aids in monitoring endemic complications, underscoring its ongoing relevance in global .

Definition and Background

What is Anti-streptolysin O?

Anti-streptolysin O (ASO) is an (IgM) antibody directed against streptolysin O, a hemolytic secreted by beta-hemolytic bacteria of groups A, C, and G. This antibody forms part of the host's to neutralize the toxin's cytolytic effects on host cells. The discovery of ASO traces back to the early , when researchers investigated streptococcal toxins and their antigenic properties. In 1932, E. W. Todd characterized an antigenic streptococcal , later identified as streptolysin O, and demonstrated its ability to elicit specific antistreptolysin reactions in serum. This work laid the foundation for understanding ASO as a serological marker of streptococcal exposure. ASO specifically targets the oxygen-labile of streptolysin O, which distinguishes it from other streptococcal antibodies such as anti-DNase B that respond to different bacterial enzymes. This targeted binding inhibits the toxin's hemolytic activity, highlighting ASO's role in countering the oxygen-sensitive nature of streptolysin O.

Streptolysin O and Streptococcal Infections

Streptolysin O (SLO) is a cholesterol-dependent cytolysin, a type of bacterial that binds specifically to in host cell membranes. Upon binding, SLO monomers oligomerize to form large transmembrane pores, which disrupt membrane integrity, leading to cell lysis, , and subsequent tissue damage during . This pore-forming mechanism allows the to contribute to the pathogenicity of streptococcal bacteria by damaging eukaryotic cells, including erythrocytes and immune cells. Unlike other streptococcal hemolysins, SLO is oxygen-labile, meaning it is inactivated upon exposure to oxygen, which distinguishes it from the oxygen-stable streptolysin S. SLO is primarily produced by (group A Streptococcus, or GAS), as well as certain strains of Streptococcus equisimilis (group C) and (group G). These beta-hemolytic streptococci release SLO as a key during infection, enhancing bacterial invasion and survival in host tissues. In GAS infections, SLO facilitates the spread of the pathogen by lysing host cells and impairing immune responses, playing a critical role in both superficial and invasive diseases. For instance, it contributes to the tissue destruction seen in (strep throat), (a superficial ), and more severe conditions like or bacteremia. Group C and G streptococci, though less commonly implicated, can produce SLO in similar zoonotic or human infections, leading to comparable clinical manifestations. Streptococcal infections involving SLO production are most prevalent in children, particularly those aged 5 to 15 years, where GAS accounts for 15-30% of acute cases and a significant portion of outbreaks in tropical regions. Untreated infections can progress to suppurative complications, such as or cervical lymphadenitis from local spread, or non-suppurative sequelae like acute and post-streptococcal due to systemic effects. These complications highlight the importance of early intervention, as SLO-mediated damage exacerbates disease severity and long-term morbidity in susceptible populations. The host to SLO generates anti-streptolysin O antibodies, which serve as markers of recent .

Pathophysiology

Mechanism of Streptolysin O

Streptolysin O (SLO) is a secreted exotoxin produced by Streptococcus pyogenes, belonging to the cholesterol-dependent cytolysin (CDC) family of pore-forming toxins. It consists of a single polypeptide chain with a molecular mass of approximately 60 kDa and comprises four β-sheet-rich domains (D1–D4). Domain 1 features a core β-sheet flanked by α-helices and loops, domain 2 contains a three-stranded β-sheet, domain 3 includes a five-stranded β-sheet with two transmembrane-spanning α-helices (TMH1 and TMH2), and domain 4 forms a β-sandwich structure critical for membrane interaction. The toxin's activity requires a reducing environment, as it is oxygen-labile due to oxidation of a conserved residue (Cys530); , activity is restored by reducing agents such as (DTT) or . Upon reduction, water-soluble SLO monomers bind to in eukaryotic membranes via a conserved threonine-leucine dyad (Thr561-Leu562) in the undecapeptide loop of domain 4, initiating a multi-step assembly process. Monomers oligomerize into large arc- or ring-shaped complexes of 30–50 monomers, which undergo conformational changes to insert TMH1 and TMH2 into the bilayer, forming transmembrane pores with diameters of 25–30 nm. These pores compromise membrane integrity by allowing uncontrolled ion flux and leakage, leading to cell lysis, particularly in cholesterol-rich targets like erythrocytes (causing β-hemolysis). At sublytic concentrations, SLO triggers in host cells through calcium influx and activation of pathways, while also promoting via stimulation of release and signaling cascades such as . SLO preferentially targets the plasma membranes of erythrocytes, leukocytes (including macrophages and neutrophils), and endothelial cells, facilitating bacterial invasion by lysing for immune evasion and disrupting vascular barriers to enhance tissue dissemination. This pore-forming mechanism underlies SLO's role as a key in streptococcal infections, prompting the host to produce neutralizing antibodies such as anti-streptolysin O.

Antibody Response and Cross-Reactivity

Upon exposure to streptolysin O, a cholesterol-binding toxin produced by group A Streptococcus during infection, B cells are activated in the host immune system, leading to the production of specific antibodies. The initial response is dominated by IgM anti-streptolysin O (ASO) antibodies, which begin to rise approximately 1 week after infection and peak at 3-6 weeks post-infection. This timeline reflects the adaptive immune activation following streptococcal pharyngitis or skin infection, with detectable ASO levels serving as a serological marker of recent exposure. ASO antibody levels typically decline gradually after the peak, returning to baseline within 6-12 months in uncomplicated cases, though reinfection or chronic exposure can prolong elevation. In patients receiving long-term penicillin prophylaxis to prevent recurrent rheumatic fever, prevention of reinfections avoids secondary rises in ASO titers, allowing the natural decline to baseline levels. The early IgM response wanes as class switching occurs, resulting in persistent IgG ASO in chronic or recurrent infections, which may contribute to sustained immune against the . Cross-reactivity arises through molecular mimicry, where anti-streptococcal antibodies share epitopes with human proteins, potentially triggering autoimmune responses. This mimicry is implicated in the of acute , where antibodies bind to cardiac and joint tissues, and post-streptococcal glomerulonephritis, involving renal structures, though ASO itself primarily serves as an indicator rather than the direct pathogenic agent.

Clinical Significance

Associated Diseases

Elevated levels of anti-streptolysin O (ASO) are strongly associated with several post-streptococcal sequelae, particularly those arising from immune-mediated responses to group A (GAS) infections. These conditions highlight the role of ASO as a marker of recent streptococcal exposure, though the antibody's elevation reflects the preceding infection rather than directly causing the disease manifestations. Acute rheumatic fever (ARF) represents one of the primary post-streptococcal disorders linked to elevated ASO titers, occurring as an autoimmune response following untreated GAS . In ARF, molecular mimicry between streptococcal antigens and host tissues triggers an immune attack on the heart (), joints (migratory ), skin (), and central nervous system (), leading to symptoms such as fever, joint pain, valvular heart inflammation, and involuntary movements. relies on the revised Jones criteria, which require of antecedent GAS infection—often indicated by ASO elevation in approximately 80% of cases—along with major manifestations like or , or minor features such as and fever. Post-streptococcal glomerulonephritis (PSGN) is another key condition tied to heightened ASO levels, characterized by immune complex deposition in the renal glomeruli following GAS infection. Elevated ASO titers are observed in more than 95% of PSGN cases. This leads to acute inflammation manifesting as , , periorbital , and , typically developing 1-3 weeks after or caused by nephritogenic strains of GAS. The immune complexes form from circulating antibodies against streptococcal antigens, depositing in the kidneys and activating complement, which differentiates PSGN pathophysiologically from the direct tissue mimicry seen in ARF. Scarlet fever, an acute toxin-mediated illness from erythrogenic toxin-producing GAS strains, also correlates with elevated ASO as evidence of recent infection, though it is not a post-infectious like ARF or PSGN. It presents with a characteristic sandpaper-like erythematous rash, strawberry tongue, and fever, driven by effects of the pyrogenic exotoxins rather than or immune complexes. ASO titers rise in response to the underlying , confirming GAS involvement in the acute phase. Rarer associations with elevated ASO include isolated , a neurological manifestation of ARF involving inflammation and choreiform movements, often occurring without other ARF signs but still linked to preceding GAS via ASO seropositivity. Additionally, —a featuring tender, erythematous nodules on the shins—has been reported in post-streptococcal contexts, with ASO elevation supporting recent GAS as the trigger for this hypersensitivity reaction.

Diagnostic Role

Anti-streptolysin O (ASO) testing is indicated in patients with suspected acute , post-streptococcal , or lingering symptoms after a streptococcal , where direct evidence of recent is needed to support . It is especially valuable when using paired acute and convalescent sera, as a fourfold or greater rise in ASO between samples collected 2-4 weeks apart provides strong evidence of a preceding streptococcal . The ASO test detects antibodies indicative of 80-85% of recent pharyngeal streptococcal infections and cases, offering moderate sensitivity that improves when combined with other serologic markers like anti-DNase B, though it alone complements throat cultures or rapid tests for retrospective confirmation in non-suppurative sequelae. According to guidelines, ASO elevation is a key minor criterion in the Jones criteria for diagnosing acute , helping verify antecedent streptococcal infection when cultures are negative. Suggestive thresholds include titers exceeding 200-250 IU/mL in adults, with lower age-adjusted cutoffs for children (e.g., >150 IU/mL in those under 5 years) to account for baseline variations. In the modern diagnostic landscape of 2025, ASO retains clinical utility despite the rise of PCR-based s for direct detection, particularly in resource-limited settings where serological tests are more feasible, affordable, and require minimal for confirming post-infectious complications.

Laboratory Assessment

Measurement Techniques

The measurement of anti-streptolysin O (ASO) antibodies originated with the neutralization developed by E. W. Todd in 1932. This historical method quantifies ASO by assessing the ability of patient serum to inhibit the hemolytic activity of streptolysin O on erythrocytes, where the is expressed in Todd units representing the reciprocal of the highest serum dilution that prevents . The procedure involves serial dilutions of serum mixed with a fixed amount of streptolysin O, followed by addition of 5% erythrocyte suspension and incubation to observe hemolysis inhibition, with results calibrated against a international standard established in 1961 equating 1 Todd unit to 1 international unit (IU). For routine screening, latex tests serve as a rapid, inexpensive qualitative or semi-quantitative alternative, widely adopted since the 1970s. These slide-based assays use latex particles coated with streptolysin O ; patient serum is mixed with the reagent on a slide, and visible agglutination within 2-3 minutes indicates ASO presence at levels typically above 200 IU/mL, providing a quick preliminary assessment suitable for point-of-care or low-resource settings. Quantitative methods, including enzyme-linked immunosorbent assay ()—which have been available since the late 1970s—and nephelometry—which was in use by the —are preferred in modern clinical laboratories for their and precision. involves immobilizing streptolysin O on microplates, adding diluted serum to bind ASO antibodies, followed by detection with enzyme-conjugated secondary antibodies and colorimetric readout, achieving titers in IU/mL with sensitivity down to approximately 10 IU/mL. Nephelometry, an automated turbidimetric technique, measures light scatter from antigen-antibody complexes formed between ASO and streptolysin O in solution, offering high throughput and comparable sensitivity to , often integrated into analyzers for precise quantification. ASO testing requires serum obtained from venous blood collection, typically 1-2 mL, separated by centrifugation within 2 hours to avoid hemolysis. Serum samples remain stable for up to 7 days when refrigerated at 2-8°C, allowing for transport to reference laboratories without significant degradation.

Interpretation and Limitations

The interpretation of anti-streptolysin O (ASO) titers relies on established reference ranges that vary by age, population, and laboratory method. Reference values (as of Mayo Clinic Laboratories) include ≤70 IU/mL for children under 5 years, ≤640 IU/mL for ages 5–17 years, and ≤530 IU/mL for adults 18 years and older; values exceeding these thresholds suggest possible prior infection but must account for method-specific variations across labs. A single elevated ASO titer indicates a likely recent , as antibodies peak 3-5 weeks post-infection and remain detectable for months. However, confirmation of an acute requires paired samples collected 2-4 weeks apart, where a fourfold or greater rise in provides stronger evidence of recent exposure. ASO testing has notable limitations, including up to a 20% false-negative rate, particularly in early infections (within the first week) when antibody levels have not yet risen, or in cases like acute where up to 20% of patients show no elevation. False positives can occur in conditions such as , , or due to elevated beta-lipoproteins interfering with the . Additionally, ASO titers decline slowly over 6-12 months, making the test unsuitable for diagnosing acute infections or distinguishing recent from remote exposures. Early antibiotic treatment may blunt the initial antibody response if administered very early, potentially resulting in lower titers or false-negative results, but generally does not significantly alter the subsequent decline pattern. Penicillin prophylaxis, commonly used in patients with a history of acute rheumatic fever to prevent recurrent group A streptococcal infections, does not directly affect the rate of ASO titer decline but prevents secondary rises in titers due to reinfections, allowing the natural gradual decline to baseline over 6-12 months without additional elevations. In patients with rheumatic valvular disease receiving penicillin prophylaxis, ASO titers decline similarly to those without valvular involvement. Alternatives to ASO include anti-DNase B testing, which offers higher sensitivity (up to 95% when combined with ASO) for detecting prior infections, especially those involving skin such as . For acute diagnosis in contemporary settings, molecular tests like PCR provide direct detection from throat swabs with greater speed and specificity than .

References

  1. https://www.ucsfhealth.org/medical-tests/antistreptolysin-o-titer
  2. https://www.testing.com/tests/antistreptolysin-o-aso/
  3. https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=167&contentid=strep_aso_titer_blood
  4. https://pediatric.testcatalog.org/show/ASO
  5. https://emedicine.medscape.com/article/240337-workup
  6. https://emedicine.medscape.com/article/2113540-reference
  7. https://www.sciencedirect.com/topics/immunology-and-microbiology/anti-streptolysin-o
  8. https://pubmed.ncbi.nlm.nih.gov/16431917/
  9. https://mjmr.journals.ekb.eg/article_331399.html
  10. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.507092/full
  11. https://rupress.org/jem/article/55/2/267/10241/ANTIGENIC-STREPTOCOCCAL-HEMOLYSIN
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2132091/
  13. https://emedicine.medscape.com/article/2113540-overview
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC4505022/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4213296/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC143243/
  17. https://journals.asm.org/doi/10.1128/mbio.00387-12
  18. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003394
  19. https://www.uptodate.com/contents/group-c-and-group-g-streptococcal-infection
  20. https://www.ncbi.nlm.nih.gov/books/NBK525997/
  21. https://www.ncbi.nlm.nih.gov/books/NBK587100/
  22. https://www.ncbi.nlm.nih.gov/books/NBK559240/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4323271/
  24. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/streptolysin-o
  25. https://pubmed.ncbi.nlm.nih.gov/3880730/
  26. https://doi.org/10.1128/iai.47.1.52-60.1985
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC2613605/
  28. https://journals.asm.org/doi/10.1128/iai.68.11.6384-6390.2000
  29. https://journals.lww.com/pidj/fulltext/2015/11000/streptococcal_serology__secrets_for_the_specialist.20.aspx
  30. https://pathlabs.ufl.edu/tests/test-directory-a/antistreptolysin-o-aso-antibodies/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC3357621/
  32. https://www.scantibodies.com/aso/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6684244/
  34. https://www.ncbi.nlm.nih.gov/books/NBK538255/
  35. https://www.ncbi.nlm.nih.gov/books/NBK425394/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4071421/
  37. https://www.ahajournals.org/doi/10.1161/cir.0000000000000205
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8730744/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC7151996/
  40. https://www.ncbi.nlm.nih.gov/books/NBK507889/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2504399/
  42. https://www.ncbi.nlm.nih.gov/books/NBK607260/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2364433/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC6374571/
  45. https://ep.bmj.com/content/99/6/231.full.pdf
  46. https://www.ahajournals.org/doi/10.1161/circulationaha.109.191959
  47. https://academic.oup.com/ofid/article/9/Supplement_1/S41/6697942
  48. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270865/pdf/jcm00134-0206.pdf
  49. https://www.annclinlabsci.org/content/16/2/163.full.pdf
  50. https://www.researchgate.net/publication/45095107_International_Standard_for_Antistreptolysin-O
  51. https://journals.asm.org/doi/10.1128/jcm.28.3.413-415.1990
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC268573/
  53. https://pubmed.ncbi.nlm.nih.gov/7726133/
  54. https://www.myco-instrumentation.com/web/content/298607
  55. https://publications.aap.org/pediatrics/article-abstract/101/1/86/52329
  56. https://www.aafp.org/pubs/afp/issues/2005/0515/p1949.html
  57. https://pubmed.ncbi.nlm.nih.gov/5682941/
  58. https://arupconsult.com/content/streptococcal-disease-group
Add your contribution
Related Hubs
User Avatar
No comments yet.